Neural Regeneration Research ›› 2019, Vol. 14 ›› Issue (3): 437-440.doi: 10.4103/1673-5374.245463

Previous Articles     Next Articles

 Multitarget therapeutic strategies for Alzheimer’s disease

Mostafa M. Ibrahim 1, 2 , Moustafa T. Gabr 3, 4   

  1. 1 Department of Pharmacognosy, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt
    2 Department of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, LA, USA
    3 Department of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt
    4 Department of Chemistry, University of Iowa, Iowa City, IA, USA
  • Online:2019-03-15 Published:2019-03-15
  • Contact: Moustafa T. Gabr, MSc, gabr2003@gmail.com.

PDF

149

Abstract:

Neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’s diseases have multifaceted nature because of the different factors contributing to their progression. The complex nature of neurodegenerative diseases has developed a pressing need to design multitarget-directed ligands to address the complementary pathways involved in these diseases. The major enzyme targets for development of therapeutics for Alzheimer’s disease are cholinesterase and β-secretase enzymes. In this review, we discuss recent advances in profiling single target inhibitors based on these enzymes to multitarget-directed ligands as potential therapeutics for this devastating disease. In addition, therapeutics based on iron chelation strategy are discussed as well.

Key words: multitarget-directed ligands, acetylcholinesterase, β-secretase, Alzheimer’s disease, hybridization, neurodegenerative diseases, tacrine, brain permeability